Sharp Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	1.73	0.44	0.51
Research & Development	3.53	2.09	1.73
Other Operating Expenses	0.25	0.01	0.03
Total Operating Expenses	5.51	2.54	2.27
Operating Income	-5.51	-2.54	-2.27
Interest Income	0	-	-
Interest Expense	-0.17	-0.17	-0.17
Other Non-Operating Income (Expense)	-0.49	-0.55	-1.12
Total Non-Operating Income (Expense)	-0.66	-0.72	-1.3
Pretax Income	-6.17	-3.26	-3.56
Net Income	-6.17	-3.26	-3.56
Net Income to Common	-6.17	-3.26	-3.56
Shares Outstanding (Basic)	29	9	4
Shares Outstanding (Diluted)	29	9	4
Shares Change (YoY)	227.36%	107.12%	-
EPS (Basic)	-0.21	-0.36	-0.82
EPS (Diluted)	-0.21	-0.36	-0.82
Free Cash Flow	-4.83	-3.63	-1.97
Free Cash Flow Per Share	-0.16	-0.40	-0.45
EBITDA	-5.41	-2.44	-2.15
EBIT	-5.51	-2.54	-2.27